226 related articles for article (PubMed ID: 22244019)
1. Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.
Lau YJ; Chen YH; Huang CT; Lee WS; Liu CY; Liu JW; Liu HD; Lee YJ; Chen CW; Ko WC; Hsueh PR
J Microbiol Immunol Infect; 2012 Feb; 45(1):1-6. PubMed ID: 22244019
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
Chen CW; Ming CC; Ma CJ; Shan YS; Yeh YS; Wang JY
Surg Infect (Larchmt); 2013 Aug; 14(4):389-96. PubMed ID: 23859673
[TBL] [Abstract][Full Text] [Related]
3. Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections.
Cheadle W; Lee JT; Napolitano LM; Nichols RL
Surg Infect (Larchmt); 2010 Oct; 11(5):487-94. PubMed ID: 20583956
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Goldstein EJ; Solomkin JS; Citron DM; Alder JD
Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).
Hsueh PR; Badal RE; Hawser SP; Hoban DJ; Bouchillon SK; Ni Y; Paterson DL;
Int J Antimicrob Agents; 2010 Nov; 36(5):408-14. PubMed ID: 20728316
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
De Waele JJ; Tellado JM; Alder J; Reimnitz P; Jensen M; Hampel B; Arvis P
Int J Antimicrob Agents; 2013 Jan; 41(1):57-64. PubMed ID: 23153963
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.
Chen YH; Hsueh PR; Badal RE; Hawser SP; Hoban DJ; Bouchillon SK; Ni Y; Paterson DL
J Infect; 2011 Apr; 62(4):280-91. PubMed ID: 21382411
[TBL] [Abstract][Full Text] [Related]
9. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
Ko WC; Hsueh PR
J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
[TBL] [Abstract][Full Text] [Related]
10. Clinical challenges and unmet needs in the management of complicated intra-abdominal infections.
Mazuski JE
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-49-69. PubMed ID: 23577497
[TBL] [Abstract][Full Text] [Related]
11. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Simoens S
Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
[TBL] [Abstract][Full Text] [Related]
12. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region.
Hsueh PR; Hoban DJ; Carmeli Y; Chen SY; Desikan S; Alejandria M; Ko WC; Binh TQ
J Infect; 2011 Aug; 63(2):114-23. PubMed ID: 21669223
[TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.
Mu YP; Liu RL; Wang LQ; Deng X; Zhu N; Wei MD; Wang Y
Int J Clin Pract; 2012 Feb; 66(2):210-7. PubMed ID: 22257046
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
Balfour JA; Lamb HM
Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of patients with community-acquired complicated intra-abdominal infections: a prospective, multicentre, observational study.
Jean SS; Ko WC; Xie Y; Pawar V; Zhang D; Prajapati G; Mendoza M; Kiratisin P; Ramalheira E; Castro AP; Rosso F; Hsueh PR
Int J Antimicrob Agents; 2014 Sep; 44(3):222-8. PubMed ID: 25106073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
